598 related articles for article (PubMed ID: 17384438)
1. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.
Gheorghiade M; Konstam MA; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C;
JAMA; 2007 Mar; 297(12):1332-43. PubMed ID: 17384438
[TBL] [Abstract][Full Text] [Related]
2. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
Konstam MA; Gheorghiade M; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C;
JAMA; 2007 Mar; 297(12):1319-31. PubMed ID: 17384437
[TBL] [Abstract][Full Text] [Related]
3. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
Gheorghiade M; Gattis WA; O'Connor CM; Adams KF; Elkayam U; Barbagelata A; Ghali JK; Benza RL; McGrew FA; Klapholz M; Ouyang J; Orlandi C;
JAMA; 2004 Apr; 291(16):1963-71. PubMed ID: 15113814
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment.
Vaduganathan M; Gheorghiade M; Pang PS; Konstam MA; Zannad F; Swedberg K; Grinfeld L; Burnett JC; Krasa HB; Zimmer C; Blair J; Ouyang J; Maggioni AP;
J Cardiovasc Med (Hagerstown); 2012 Jul; 13(7):415-22. PubMed ID: 22673023
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).
Gheorghiade M; Orlandi C; Burnett JC; Demets D; Grinfeld L; Maggioni A; Swedberg K; Udelson JE; Zannad F; Zimmer C; Konstam MA
J Card Fail; 2005 May; 11(4):260-9. PubMed ID: 15880334
[TBL] [Abstract][Full Text] [Related]
6. Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial.
Ambrosy AP; Khan H; Udelson JE; Mentz RJ; Chioncel O; Greene SJ; Vaduganathan M; Subacuis HP; Konstam MA; Swedberg K; Zannad F; Maggioni AP; Gheorghiade M; Butler J
Circ Heart Fail; 2016 May; 9(5):. PubMed ID: 27140204
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure.
Felker GM; Mentz RJ; Cole RT; Adams KF; Egnaczyk GF; Fiuzat M; Patel CB; Echols M; Khouri MG; Tauras JM; Gupta D; Monds P; Roberts R; O'Connor CM
J Am Coll Cardiol; 2017 Mar; 69(11):1399-1406. PubMed ID: 27654854
[TBL] [Abstract][Full Text] [Related]
8. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
Gheorghiade M; Niazi I; Ouyang J; Czerwiec F; Kambayashi J; Zampino M; Orlandi C;
Circulation; 2003 Jun; 107(21):2690-6. PubMed ID: 12742979
[TBL] [Abstract][Full Text] [Related]
9. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program.
Blair JE; Zannad F; Konstam MA; Cook T; Traver B; Burnett JC; Grinfeld L; Krasa H; Maggioni AP; Orlandi C; Swedberg K; Udelson JE; Zimmer C; Gheorghiade M;
J Am Coll Cardiol; 2008 Nov; 52(20):1640-8. PubMed ID: 18992654
[TBL] [Abstract][Full Text] [Related]
10. Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload.
Konstam MA; Kiernan M; Chandler A; Dhingra R; Mody FV; Eisen H; Haught WH; Wagoner L; Gupta D; Patten R; Gordon P; Korr K; Fileccia R; Pressler SJ; Gregory D; Wedge P; Dowling D; Romeling M; Konstam JM; Massaro JM; Udelson JE;
J Am Coll Cardiol; 2017 Mar; 69(11):1409-1419. PubMed ID: 28302292
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction.
Udelson JE; Bilsker M; Hauptman PJ; Sequeira R; Thomas I; O'Brien T; Zimmer C; Orlandi C; Konstam MA
J Card Fail; 2011 Dec; 17(12):973-81. PubMed ID: 22123358
[TBL] [Abstract][Full Text] [Related]
12. Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
Greene SJ; Gheorghiade M; Vaduganathan M; Ambrosy AP; Mentz RJ; Subacius H; Maggioni AP; Nodari S; Konstam MA; Butler J; Filippatos G;
Eur J Heart Fail; 2013 Dec; 15(12):1401-11. PubMed ID: 23845795
[TBL] [Abstract][Full Text] [Related]
13. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan.
Hauptman PJ; Burnett J; Gheorghiade M; Grinfeld L; Konstam MA; Kostic D; Krasa HB; Maggioni A; Ouyang J; Swedberg K; Zannad F; Zimmer C; Udelson JE;
J Card Fail; 2013 Jun; 19(6):390-7. PubMed ID: 23743487
[TBL] [Abstract][Full Text] [Related]
14. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction.
Udelson JE; McGrew FA; Flores E; Ibrahim H; Katz S; Koshkarian G; O'Brien T; Kronenberg MW; Zimmer C; Orlandi C; Konstam MA
J Am Coll Cardiol; 2007 Jun; 49(22):2151-9. PubMed ID: 17543634
[TBL] [Abstract][Full Text] [Related]
15. EVEREST study: Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan.
Cavalcante JL; Khan S; Gheorghiade M
Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1331-8. PubMed ID: 19018685
[TBL] [Abstract][Full Text] [Related]
16. Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure.
Ter Maaten JM; Valente MA; Damman K; Cleland JG; Givertz MM; Metra M; O'Connor CM; Teerlink JR; Ponikowski P; Bloomfield DM; Cotter G; Davison B; Subacius H; van Veldhuisen DJ; van der Meer P; Hillege HL; Gheorghiade M; Voors AA
Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27266853
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study).
Matsuzaki M; Hori M; Izumi T; Fukunami M;
Cardiovasc Drugs Ther; 2011 Dec; 25 Suppl 1():S33-45. PubMed ID: 22120092
[TBL] [Abstract][Full Text] [Related]
18. Contrasting acute and chronic effects of tolvaptan on serum osmolality in the EVEREST trial.
Vaduganathan M; Goldsmith SR; Senni M; Butler J; Gheorghiade M
Eur J Heart Fail; 2016 Feb; 18(2):185-91. PubMed ID: 26443242
[TBL] [Abstract][Full Text] [Related]
19. Differences in pharmacological property between combined therapy of the vasopressin V2-receptor antagonist tolvaptan plus furosemide and monotherapy of furosemide in patients with hospitalized heart failure.
Takagi K; Sato N; Ishihara S; Iha H; Kobayashi N; Ito Y; Nohara T; Ohkuma S; Mitsuishi T; Ishizuka A; Shigihara S; Sone M; Nakama K; Tokuyama H; Omote T; Kikuchi A; Nakamura S; Yamamoto E; Ishikawa M; Amitani K; Takahashi N; Maruyama Y; Imura H; Shimizu W
J Cardiol; 2020 Nov; 76(5):499-505. PubMed ID: 32665162
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of costs associated with tolvaptan-mediated length-of-stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial.
Chiong JR; Kim S; Lin J; Christian R; Dasta JF
J Med Econ; 2012; 15(2):276-84. PubMed ID: 22111754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
